Interventional cardiologists say some cases that coders flag and submit to the NCDR aren’t in fact problematic.

Gene-editing therapy, ACS guidelines, and the death of Dimitrios Karmpaliotis were some of TCTMD’s most-read stories this ...

Cardiovascular imaging, which continues to evolve alongside interventions and other technologies, made notable strides in the ...

The year saw the emergence of a new version of an old drug that proved beneficial in patients who have heart failure with ...

Interventionalists don’t often order a CXR ahead of time, but when it’s already been done, some find the added info useful.

A steady stream of structural trial data, approvals, reimbursement decisions, and real-world rollouts arrived in 2025.

Advances in the treatment of coronary artery disease remained steady in 2025, as in recent years, but the past 12 months also ...

CLOSURE-AF and CREST-2 were widely read, but stories on GLP-1s, DOACs in AF, and a new PCSK9 inhibitor were popular, too.

Other hot topics included new data on LAAO and conduction-system pacing, plus the go-ahead for ablation in ASCs.

The drug is the second cardiac myosin inhibitor to get regulatory signoff in the United States, following mavacamten in 2022.

VESALIUS-CV was big in 2025, but studies looking at triglycerides, CRISPR, and oral GLP-1s also made the highlight reel.

Government entities threw CV specialists for a loop in 2025 with changes that will inevitably affect patient care.